Ivan Hyep Sells 2,963 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 2,963 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.25, for a total value of $54,074.75. Following the completion of the transaction, the chief financial officer directly owned 145,355 shares in the company, valued at $2,652,728.75. This represents a 2.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $246,972.10.
• On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total value of $34,158.30.

Bicara Therapeutics Stock Down 0.2%

Shares of Bicara Therapeutics stock opened at $18.47 on Friday. The stock’s fifty day moving average is $16.47 and its 200-day moving average is $15.75. The firm has a market capitalization of $1.01 billion, a PE ratio of -8.25 and a beta of -0.78. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $19.71.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds have recently bought and sold shares of BCAX. Deutsche Bank AG grew its stake in Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after acquiring an additional 1,171 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter. Mariner LLC boosted its holdings in shares of Bicara Therapeutics by 3.0% during the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after purchasing an additional 1,902 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Bicara Therapeutics by 13.2% during the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after purchasing an additional 1,962 shares during the period.

Analysts Set New Price Targets

Several analysts have issued reports on BCAX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Wedbush reissued an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Finally, UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $28.33.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.